Methamphetamine Isomer Pharmacology in Humans

Part of paid clinical trials in Madison, Wisconsin.

Sponsor
University of Wisconsin, Madison
Study ID
NCT06746831
Phase
PHASE1
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Methamphetamine

Eligibility Criteria

Sex
ALL
Age
21 Years - 64 Years
Healthy Volunteers
Accepted

Interventions

  • S-(+)-methamphetamine — DRUG
    15 mg
  • R-(-)-methamphetamine — DRUG
    15 mg
  • 1:1 racemic mixture of two isomers — DRUG
    15 mg R-Meth + 15 mg S-Meth

Study Details

This study is being done to understand the metabolism and impairment profile of methamphetamine (meth). Meth exists as two chemical structures that are mirror images of each other: R-meth and S-meth. S-meth is a strong central nervous system stimulant and used to treat attention deficit disorder (ADD). R-meth is not a strong central nervous system stimulant and is available over-the-counter in nasal decongestant sprays.17 healthy participants will be enrolled for 3 study visits and on study for up to 12 weeks.

Key Dates

Start date
Jun 30, 2026
Status verified
Apr 2026
Primary completion
Mar 31, 2028
Completion
Mar 31, 2028

Study Design

Enrollment
17 participants (estimated)
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT

Arms

  • Experimental: S-Meth, R-Meth, Racemic Isomer
    First visit: Administer S-Meth, then at least 7 days later Second visit: Administer R-Meth, then at least 7 days later Third visit: Administer (1:1) racemic methamphetamine
  • Experimental: R-Meth, Racemic Isomer, S-Meth
    First visit: Administer R-Meth, then at least 7 days later Second visit: Administer (1:1) racemic methamphetamine, then at least 7 days later Third visit: Administer S-Meth
  • Experimental: Racemic Isomer, S-Meth, R-Meth
    First visit: Administer (1:1) racemic methamphetamine, then at least 7 days later Second visit: Administer S-Meth, then at least 7 days later Third visit: Administer R-Meth

Primary Outcome Measure

Peak concentration (Cmax) [ Time Frame: pre-dose, 0, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 16, 20, 24, 30, 36, 42, 48 hours ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
University of WisconsinMadisonWisconsin53705-

Find similar trials in Madison, WI

By research site
University of Wisconsin· Madison, WI